ClinicalTrials.gg
RecruitingNCT07528326TRICURE US IDEUpdated Oct 22, 2026

The TRICURE US IDE Pivotal Study

An interventional study of TRiCares Topaz TTVR System and Edwards EVOQUE TTVR System in Tricuspid Regurgitation (TR), sponsored by TRiCares. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-22.

Sponsored by TRiCares · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2026; still recruiting 4 months later.
Updated Oct 22, 2026Now RecruitingFirst site in United States+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
831
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 60 studies in Tricuspid Valve Insufficiency with a site in United States — 27 open to participants now, 36 under way, none of them phase 3. Tricuspid Valve Insufficiency · United States.

Planned enrollment
4th of 42
831 · median 63
Started
2026
with 9 others
No phase
39 of 60
18 open now
Primary completion
2031-09
later than 33 of 35 live
Registered
56th of 60
by date
Lead sponsor
2 of 60
TRiCares

Among the 60 studies in Tricuspid Valve Insufficiency with a site in United States, this one is the 4th largest by planned enrollment of the 42 interventional ones that give a count, is one of 10 that started in 2026, is one of 39 with no phase, reaches primary completion later than 33 of the 35 other live ones, and was the 56th registered.

Tricuspid Valve Insufficiency

229 studies on the registry are indexed under Tricuspid Valve Insufficiency; 111 are open to participants now.

Browse Tricuspid Valve Insufficiency studies →

Open to participants now

27 of the 60 studies in Tricuspid Valve Insufficiency with a site in United States are open now. Recruiting first, the newest first:

21 more — sign in →

All 27 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 81 Tricuspid Valve Insufficiency studies recruiting now, 67 (83%) set no upper age limit and none (0%) stop at 75 or younger; 7 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 60 studies in Tricuspid Valve Insufficiency with a site in United States, or all of them as a file.
02

Study summary

The purpose of the study is to evaluate safety and effectiveness of the TRiCares Topaz TTVR system for treatment of subjects presenting with clinically relevant tricuspid regurgitation who are suitable for valve replacement.

Read the detailed description

The TRICURE US IDE Pivotal Study is a prospective, global, multi-center, randomized (1:1) controlled study (RCT) designed to evaluate the safety and effectiveness of the TRiCares Topaz TTVR System compared to the Edwards EVOQUE TTVR System in subjects with severe or greater tricuspid regurgitation.

03

Conditions studied

  • Tricuspid Regurgitation (TR)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient is ≥ 18 years of age
  • Patient has severe or greater tricuspid regurgitation with symptoms despite optimal medical therapy
  • Patient is an appropriate candidate to undergo TTVR as determined by the Institution Heart Team

Exclusion criteria

Exclusion Criteria:

  • Patient has a tricuspid device currently in place
  • Patient has anatomical
  • Patient is in need of urgent surgery
  • Patient has a of \< 25%
  • Patient has of \< 1 year
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
831 participants (estimated)

Study arms

  • Experimental
    TRiCares Topaz TTVR

    Transcatheter tricuspid valve replacement with TRiCares Topaz TTVR

    Device: TRiCares Topaz TTVR System

  • Active comparator
    Edwards EVOQUE TTVR

    Transcatheter tricuspid valve replacement with Edwards EVOQUE TTVR

    Device: Edwards EVOQUE TTVR System

  • Experimental
    Single Arm Registry

    Patients eligible to receive the TRiCares Topaz TTVR system, but not eligible for the Edwards EVOQUE system will be enrolled in the non-randomized, single-arm registry and treated with Topaz TTVR.

    Device: TRiCares Topaz TTVR System

Interventions

  • DeviceTRiCares Topaz TTVR System

    TRiCares Topaz TTVR System

  • DeviceEdwards EVOQUE TTVR System

    Edwards EVOQUE TTVR System

  • DeviceTRiCares Topaz TTVR System

    TRiCares Topaz TTVR System

06

What researchers measure

Primary outcomes

  1. Rate of Major Adverse Events (MAE)

    Time frame: 30 days post-procedure

  2. Composite Endpoint

    All-cause mortality, heart failure hospitalization, non-elective tricuspid valve reintervention

    Time frame: 1 year post-procedure

Secondary outcomes

  1. Change in qualify of life (QoL)

    as measured by the Kansas City Cardiomyopathy Questionnaire (KCCQ) from baseline

    Time frame: 1 year post-procedure

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for Sep 2031, 62 months after the start.

Of 55 industry-sponsored interventional studies with no phase under Tricuspid Valve Insufficiency, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 70. This study's planned 62 months is above that.

Counting every sponsor, half of 86 studies reached it within 38 months; a quarter within 23 and three quarters within 58.

Start moved once since we started tracking on Sep 25, 2026: Oct 2026 → Jul 2026, on Oct 22, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 7, 2026
First posted
Apr 14, 2026
StartActual
Jul 8, 2026was Oct 2026
Primary completionEst.
Sep 2031
CompletionEst.
Sep 2035
Last update
Oct 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 22, 2026
Sites
1 site added — first site in United States
Show site
  • Piedmont Heart Institute · Atlanta, United States
Oct 22, 2026
Start date
Oct 2026→Jul 8, 2026 (actual)
Oct 22, 2026
Show all 1 update
  1. Oct 22, 2026
    Not yet recruiting→Recruiting
    1 site added — first site in United States
    Show site
    • Piedmont Heart Institute · Atlanta, United States
    Start date Oct 2026→Jul 8, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07528326
Lead sponsor
TRiCares
Responsible party
Sponsor
First posted
Apr 14, 2026
Start date
Jul 8, 2026
Primary completion
Sep 2031 (estimated)
Completion
Sep 2035 (estimated)
Last update
Oct 22, 2026

Study contacts

Stephanie Cihlar
Contact
cihlar@tricares.de
763-227-7833
Pradeep Yadav, MD
principal investigator · Piedmont Hospital
Neil Fam, MD
principal investigator · Unity Health Toronto

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion